|Home||Internet of Things||Aerospace||Apparel||Energy||Defense||Health Care||Logistics||Manufacturing||Retail|
SenoRx Uses Implantable RFID Tags to Mark Breast Tumors
The company's system would allow radiologists to inject a passive RFID tag into a patient's breast, to help a surgeon locate a lesion during a lumpectomy.
Dec 28, 2009—SenoRx, a provider of breast cancer treatment and diagnostic equipment, is working to introduce an RFID-based system that will offer radiologists a new method for marking a tumor's location prior to surgery. The solution, according to the company, promises to reduce the risk of infection, while helping surgeons to locate lesions more accurately.
Typically, a breast cancer patient goes through a one-day process in which a radiologist finds the tumor and then marks its location by inserting a wire into the lesion, so that one end of the wire protrudes from the breast after insertion. The radiologist then utilizes ultrasound, stereotactic or mammographic guidance to ensure that the tip of the wire is within the tumor's center. The surgeon can then follow the length of wire to its end, in order to pinpoint the specific location of the mass. This procedure usually requires a patient to schedule both radiological and surgical procedures on the same day the wire is inserted, to ensure against infection caused by the wire, as well as reduce the chance of the wire being dislodged. The wire could be jostled out of place, for example, as the patient moves around prior to the operation, or be inadvertently moved during the surgery itself; and in some cases, surgeons may have difficulty locating or identifying the end of the wire marking the lesion, or with radiographs.
The solution uses an RFID handheld reader and software from Health Beacons, as well as off-the-shelf RFID tags. SenoRx now seeks 510(k) clearance from the Food and Drug Administration (FDA), which is required for medical devices before they can be used on humans. During the 510(k) process, the FDA determines whether a device is equivalent to a previous instrument cleared by the FDA or marketed before 1976. The 510(k) submitter explains the similarity between the new device being submitted for clearance and any previously approved tools it may replace, outlining why any differences between them should be acceptable. Once it obtains 510(k) clearance, SenoRx intends to proceed into testing with live human subjects.
Login and post your comment!
Not a member?
Signup for an account now to access all of the features of RFIDJournal.com!
SEND IT YOUR WAY
RFID JOURNAL EVENTS
ASK THE EXPERTS
Simply enter a question for our experts.
TAKE THE POLL